Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2014 · 10-Q
Revenue$0.00$0.00no prior Q3 2013 on file Net Income-$153.84K-$153.84KN/M vs Q3 2013 EPS Diluted-$0.00-$0.00N/M vs Q3 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Operating Cash Flowderived$13,724— Free Cash Flowderived$13,724— ended May 31, 2015 · filed Jul 15, 2015 · 45 d after period end